Last 7 days
-17.5%
Last 30 days
-43.6%
Last 90 days
-53.2%
Trailing 12 Months
-62.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 116.8B | 26.2B | -8.85% | -12.37% | 14.75 | 4.46 | -0.48% | 38.34% |
GILD | 95.3B | 27.0B | -7.15% | 22.78% | 17.06 | 3.52 | -1.56% | 23.65% |
MRNA | 49.5B | 15.1B | -3.01% | -12.71% | 10.35 | 3.29 | -33.37% | -67.32% |
BIIB | 43.1B | 10.1B | -1.82% | 44.85% | 13.78 | 4.27 | -6.61% | 115.98% |
MID-CAP | ||||||||
NBIX | 8.8B | 1.6B | -10.82% | -3.21% | 137.28 | 5.5 | 32.38% | -10.36% |
DNLI | 4.0B | - | 17.83% | 16.01% | -10.8 | 36.9 | 122.90% | -29.67% |
BEAM | 2.4B | 76.7M | 3.87% | -11.56% | -7.51 | 30.96 | 41.73% | -32.75% |
BBIO | 2.2B | 107.9M | -6.75% | 87.02% | -4.48 | 20.12 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.5B | 119.0M | 13.50% | 5.58% | -5.31 | 12.45 | -69.61% | -584.39% |
REPL | 1.1B | 10.0M | 10.82% | 23.60% | -6.03 | 105.01 | 215.65% | -47.65% |
NVAX | 641.1M | - | -3.13% | -86.56% | -0.55 | 0.32 | 72.89% | 12.32% |
FATE | 487.0M | 136.9M | -18.29% | -78.97% | -2.07 | 3.56 | 116.83% | -0.93% |
SGMO | 191.0M | 241.0M | -22.11% | -68.89% | -1.5 | 0.79 | 113.96% | 27.87% |
VXRT | 166.8M | 697.0K | 51.20% | -67.02% | -1.55 | 239.29 | 47.98% | -35.48% |
IBIO | 9.0M | - | -32.41% | -88.55% | -0.12 | 3.21 | 0.51% | -129.47% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q1 | |
Revenue | 133.9% | 8,622,667 | 3,686,000 | - | ||
Operating Expenses | 5.4% | 321,731,000 | 305,313,000 | 305,214,000 | 233,072,000 | - |
S&GA Expenses | 17.6% | 122,124,000 | 103,829,000 | 68,523,000 | - | - |
R&D Expenses | -2.9% | 177,158,000 | 182,435,000 | 201,116,000 | 164,549,000 | - |
Interest Expenses | 33.2% | 20,856,000 | 15,652,000 | 8,737,000 | 1,838,000 | - |
Net Income | -5.1% | -327,234,000 | -311,458,000 | -310,765,000 | -234,638,000 | - |
Net Income Margin | 21.1% | -84.50 | -107 | - | - | - |
Free Cahsflow | -8.0% | -258,048,000 | -238,830,000 | -185,964,000 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -15.5% | 379 | 449 | 509 | 300 | 364 |
Current Assets | -15.9% | 368 | 437 | 497 | 295 | 359 |
Cash Equivalents | 53.5% | 82.00 | 54.00 | 82.00 | 62.00 | 70.00 |
Inventory | 13.8% | 9.00 | 8.00 | 4.00 | - | - |
Net PPE | 10.0% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | 0.0% | 240 | 240 | 238 | 105 | 110 |
Current Liabilities | -2.1% | 37.00 | 38.00 | 37.00 | 27.00 | 33.00 |
Long Term Debt | 169.0% | 197 | 73.00 | 73.00 | - | - |
LT Debt, Non Current | 0.5% | 199 | 198 | 197 | 73.00 | 73.00 |
Shareholder's Equity | -33.3% | 140 | 210 | 271 | 195 | 254 |
Retained Earnings | -11.1% | -799 | -719 | -647 | -540 | -472 |
Additional Paid-In Capital | 1.0% | 940 | 930 | 920 | 737 | 727 |
Accumulated Depreciation | 18.8% | 1.00 | 1.00 | 1.00 | - | - |
Shares Outstanding | 0.5% | 61.00 | 61.00 | 61.00 | 52.00 | 51.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -9.1% | -281 | -257 | -238 | -211 | -185 |
Share Based Compensation | 9.0% | 36.00 | 33.00 | 29.00 | 26.00 | 22.00 |
Cashflow From Investing | 106.0% | 5.00 | -87.20 | -105 | 95.00 | -122 |
Cashflow From Financing | -4.8% | 287 | 302 | 374 | 89.00 | 89.00 |
94.9%
81.7%
68%
Y-axis is the maximum loss one would have experienced if Arcutis Biotherapeutics was unfortunately bought at previous high price.
-38.5%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | sold off | -100 | -153,609 | - | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 5.05 | -2,639,930 | 9,402,070 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -19.98 | -179,000 | 264,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 23.38 | -55,000 | 605,000 | -% |
2023-05-17 | Thrivent Financial for Lutherans | unchanged | - | -129,000 | 373,000 | -% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | -1,653 | 4,785 | -% |
2023-05-16 | JANE STREET GROUP, LLC | new | - | 288,805 | 288,805 | -% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 376 | 839,824 | 1,169,890 | -% |
2023-05-16 | SRS Capital Advisors, Inc. | added | 23.53 | -41.00 | 462 | -% |
2023-05-15 | Balyasny Asset Management L.P. | new | - | 487,168 | 487,168 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | point72 asset management, l.p. | 1.8% | 1,103,576 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 08, 2023 | state street corp | 6.04% | 3,679,385 | SC 13G | |
Feb 03, 2023 | blackrock inc. | 8.6% | 5,214,258 | SC 13G/A | |
Aug 26, 2022 | orbimed advisors llc | 4.7% | 2,828,356 | SC 13D/A | |
Jun 28, 2022 | orbimed advisors llc | 6.9% | 3,534,537 | SC 13D/A | |
May 27, 2022 | bain capital life sciences fund, l.p. | 5.3% | 2,721,436 | SC 13D/A | |
Apr 08, 2022 | orbimed advisors llc | 7.6% | 3,840,564 | SC 13D/A | |
Feb 14, 2022 | point72 asset management, l.p. | 5.3% | 2,644,177 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 24, 2023 | 8-K | Current Report | |
May 09, 2023 | 10-Q | Quarterly Report | |
May 09, 2023 | 8-K | Current Report | |
Apr 18, 2023 | 4 | Insider Trading | |
Apr 18, 2023 | DEF 14A | DEF 14A | |
Apr 18, 2023 | DEFA14A | DEFA14A | |
Apr 17, 2023 | 144 | Notice of Insider Sale Intent | |
Apr 10, 2023 | 4 | Insider Trading | |
Mar 31, 2023 | 4/A | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-04-17 | Welgus Howard G. | sold | -118,728 | 13.968 | -8,500 | - |
2023-04-17 | Welgus Howard G. | acquired | 14,285 | 1.6806 | 8,500 | - |
2023-04-06 | Welgus Howard G. | acquired | 14,285 | 1.6806 | 8,500 | - |
2023-04-06 | Welgus Howard G. | sold | -102,085 | 12.01 | -8,500 | - |
2023-03-06 | Watanabe Todd Franklin | sold | -37,167 | 15.2638 | -2,435 | see remarks |
2023-03-06 | Burrows Scott L | sold | -4,441 | 15.2634 | -291 | chief financial officer |
2023-03-06 | OSBORNE DAVID W | sold | -10,531 | 15.2634 | -690 | chief technical officer |
2023-03-06 | Burnett Patrick | sold | -12,989 | 15.2634 | -851 | see remarks |
2023-03-06 | Lock Kenneth A. | sold | -12,684 | 15.2636 | -831 | chief commercial officer |
2023-03-06 | Turney Patricia A. | sold | -12,684 | 15.2635 | -831 | svp, operations |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Revenue, Product and Service [Extensible Enumeration] | Product [Member] | Product [Member] |
Total revenues | $ 2,781 | $ 0 |
Operating expenses: | ||
Cost of sales | 783 | 0 |
Research and development | 35,345 | 40,622 |
Selling, general, and administrative | 42,918 | 22,006 |
Total operating expenses | 79,046 | 62,628 |
Loss from operations | (76,265) | (62,628) |
Other income (expense): | ||
Other income, net | 3,207 | 142 |
Interest expense | (7,042) | (1,838) |
Total other income (expense) | (3,835) | (1,696) |
Other comprehensive income (loss): | ||
Unrealized income (loss) on marketable securities | 724 | (765) |
Foreign currency translation adjustment | (52) | 0 |
Total other comprehensive income (loss) | 672 | (765) |
Net loss | (80,100) | (64,324) |
Comprehensive loss | $ (79,428) | $ (65,089) |
Per share information: | ||
Net loss per share, basic (in USD per share) | $ (1.31) | $ (1.27) |
Net loss per share, diluted (in USD per share) | $ (1.31) | $ (1.27) |
Weighted-average shares used in computing net loss per share, basic (in shares) | 61,169,089 | 50,513,524 |
Weighted-average shares used in computing net loss per share, diluted (in shares) | 61,169,089 | 50,513,524 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 81,405 | $ 53,641 |
Restricted cash | 925 | 1,234 |
Trade receivables, net | 12,769 | 8,458 |
Marketable securities | 251,000 | 355,948 |
Inventories | 8,551 | 7,514 |
Prepaid expenses and other current assets | 13,026 | 10,611 |
Total current assets | 367,676 | 437,406 |
Property, plant, and equipment, net | 2,070 | 1,881 |
Intangible assets, net | 7,000 | 7,188 |
Operating lease right-of-use asset | 2,634 | 2,721 |
Other assets | 78 | 78 |
Total assets | 379,458 | 449,274 |
Current liabilities: | ||
Accounts payable | 12,485 | 8,827 |
Accrued liabilities | 23,864 | 28,323 |
Operating lease liability | 676 | 657 |
Total current liabilities | 37,025 | 37,807 |
Operating lease liability, noncurrent | 3,938 | 4,117 |
Long-term debt, net | 198,763 | 197,769 |
Total liabilities | 239,726 | 239,693 |
Commitments and contingencies (Note 7) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022; | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2023 and December 31, 2022; 61,369,061 and 61,052,250 shares issued at March 31, 2023 and December 31, 2022, respectively; 61,357,932 and 61,037,403 shares outstanding at March 31, 2023 and December 31, 2022, respectively | 6 | 6 |
Additional paid-in capital | 940,004 | 930,425 |
Accumulated other comprehensive loss | (414) | (1,086) |
Accumulated deficit | (799,864) | (719,764) |
Total stockholders’ equity | 139,732 | 209,581 |
Total liabilities and stockholders’ equity | $ 379,458 | $ 449,274 |